PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17170519-6 2006 Co-incubation with the bradykinin B2 receptor antagonist HOE 140 attenuated the omapatrilat-induced lowering of fibronectin. 4-hydroxy-2-octenal 57-60 kininogen 1 Homo sapiens 23-33 16093449-6 2005 Spectrofluorometry using fura-2-AM revealed that 100 nM BK elicited a significant increase in Ca(i), which was abolished by the receptor antagonist HOE-140. 4-hydroxy-2-octenal 148-151 kininogen 1 Homo sapiens 56-58 12384249-10 2002 The fall in TEER from bradykinin was blocked by HOE 140, U73122 and thapsigargin combined with La(3+), and also by aristolochic acid and NDGA, but not indomethacin, calphostin C or L-NAME. 4-hydroxy-2-octenal 48-51 kininogen 1 Homo sapiens 22-32 10514288-2 1999 The same modification was performed on the potent bradykinin B(2) receptor antagonist HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH), in which the -D-Tic-Oic- moiety was replaced by D-BT to yield H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-Arg-OH, 1 (JMV1116). 4-hydroxy-2-octenal 86-89 kininogen 1 Homo sapiens 50-60 11805429-7 2001 The [Ca(2+)](i )increase induced by 1 nM bradykinin in Ca(2+)- free medium was abolished by 1 nM HOE 140 (a B2 bradykinin receptor antagonist) but was not altered by 100 nM Des-Arg-HOE 140 (a B1 bradykinin receptor antagonist). 4-hydroxy-2-octenal 97-100 kininogen 1 Homo sapiens 41-51 11805429-7 2001 The [Ca(2+)](i )increase induced by 1 nM bradykinin in Ca(2+)- free medium was abolished by 1 nM HOE 140 (a B2 bradykinin receptor antagonist) but was not altered by 100 nM Des-Arg-HOE 140 (a B1 bradykinin receptor antagonist). 4-hydroxy-2-octenal 181-184 kininogen 1 Homo sapiens 41-51 9523665-10 1998 The infusion of the B2 kinin receptor antagonist Hoe 140 (50 nmol/L) virtually abolished the relaxation induced by BK, Lys-BK and Met-Lys-BK without affecting those induced by acetylcholine and histamine. 4-hydroxy-2-octenal 49-52 kininogen 1 Homo sapiens 115-117 9725250-13 1998 BK-induced IL-8 release was mimicked by the BK B2 receptor agonist (Tyr(Me)8)-BK and was potently inhibited by the selective B2 receptor antagonist HOE-140. 4-hydroxy-2-octenal 148-151 kininogen 1 Homo sapiens 0-2 9719163-6 1998 The [Ca2+]i response to bradykinin was inhibited by the BK2 antagonist Hoe 140 (IC50 +/- k7 nmol/l, n = 30). 4-hydroxy-2-octenal 71-74 kininogen 1 Homo sapiens 24-34 9523665-10 1998 The infusion of the B2 kinin receptor antagonist Hoe 140 (50 nmol/L) virtually abolished the relaxation induced by BK, Lys-BK and Met-Lys-BK without affecting those induced by acetylcholine and histamine. 4-hydroxy-2-octenal 49-52 kininogen 1 Homo sapiens 123-125 9523665-10 1998 The infusion of the B2 kinin receptor antagonist Hoe 140 (50 nmol/L) virtually abolished the relaxation induced by BK, Lys-BK and Met-Lys-BK without affecting those induced by acetylcholine and histamine. 4-hydroxy-2-octenal 49-52 kininogen 1 Homo sapiens 123-125 9514242-1 1998 The AMBER 4.0 force field was used to perform the characterization of the conformational profile of the highly potent bradykinin antagonist Hoe-140 (D-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-Ser6-D-++ +Tic7-Oic8-Arg9). 4-hydroxy-2-octenal 140-143 kininogen 1 Homo sapiens 118-128 8650249-6 1996 The administration of HOE-140, a bradykinin B2 receptor blocker, prior to PU-15, completely abolishes the anti-ANP action of PU-15. 4-hydroxy-2-octenal 22-25 kininogen 1 Homo sapiens 33-43 9224807-5 1997 The response of phosphatidylinositol hydrolysis was antagonized by the B2 receptor selective antagonist Hoe 140 (D-Arg-[hydroxyproline3,beta-thienylalanine4,D-Tic7,++ +Oic8]bradykinin). 4-hydroxy-2-octenal 104-107 kininogen 1 Homo sapiens 173-183 8910447-1 1996 The B2 bradykinin receptor, a seven-helix transmembrane receptor, binds the inflammatory mediator bradykinin (BK) and the structurally related peptide antagonist HOE-140. 4-hydroxy-2-octenal 162-165 kininogen 1 Homo sapiens 7-17 8922758-15 1996 The bradykinin antagonist, Hoe 140, 10 to 200 micrograms, given by intranasal aerosol, produced a dose-related inhibition of the reduction in minimal nasal cross-sectional area (Amin) induced by bradykinin in normal subjects and by house dust mite antigen in subjects with allergic rhinitis to house dust mite. 4-hydroxy-2-octenal 27-30 kininogen 1 Homo sapiens 4-14 8922758-15 1996 The bradykinin antagonist, Hoe 140, 10 to 200 micrograms, given by intranasal aerosol, produced a dose-related inhibition of the reduction in minimal nasal cross-sectional area (Amin) induced by bradykinin in normal subjects and by house dust mite antigen in subjects with allergic rhinitis to house dust mite. 4-hydroxy-2-octenal 27-30 kininogen 1 Homo sapiens 195-205 8876745-4 1996 This dilation could be abolished by the selective bradykinin B2-receptor antagonist Hoe 140 (2 mg kg-1 min-1, i.a. 4-hydroxy-2-octenal 84-87 kininogen 1 Homo sapiens 50-60 8964116-4 1996 Microvessels were incubated in the presence of agonists for nitric oxide production (acetylcholine and bradykinin), which caused dose-dependent increases in nitrite, a response that was blocked by NG-nitro-L-arginine methyl ester and receptor-specific antagonists (atropine and HOE 140, respectively). 4-hydroxy-2-octenal 278-281 kininogen 1 Homo sapiens 103-113 9316832-8 1997 Both the BK-induced insulin secretion and rise in [Ca++]i were inhibited by a selective BK2 receptor antagonist, HOE 140 (3.3-100 nM), in concentration-dependent manners but were not by a BK1 receptor antagonist des-Arg9,Leu8-BK (1 microM). 4-hydroxy-2-octenal 113-116 kininogen 1 Homo sapiens 9-11 9012741-10 1997 The association of losartan (10 mumol/L) with the bradykinin B2 receptor antagonist HOE 140 (1 mumol/L) totally prevented the relaxation due to the ACEI. 4-hydroxy-2-octenal 84-87 kininogen 1 Homo sapiens 50-60 8521563-3 1995 METHODS AND RESULTS: The selective bradykinin B2 receptor antagonist HOE 140 was infused into the left main coronary artery (200 micrograms/min for 15 minutes) in 15 patients without significant coronary stenoses. 4-hydroxy-2-octenal 69-72 kininogen 1 Homo sapiens 35-45 8665918-5 1996 The effect evoked by 10 nM bradykinin was rapid (2 min) and it was partially reduced by the B2-kinin-receptor antagonist Hoe 140 which was shown to be a weak inducer of tyrosine phosphorylation. 4-hydroxy-2-octenal 121-124 kininogen 1 Homo sapiens 27-37 8521563-8 1995 After bradykinin B2 receptor blockade, there was a reduction in flow-dependent dilation (23.4 +/- 6.9% to 3.9 +/- 6.0%, P < .001), the extent of which correlated with the degree of basal vasoconstriction after HOE 140 in the same vessel segment (P < .05). 4-hydroxy-2-octenal 213-216 kininogen 1 Homo sapiens 6-16 7955144-3 1994 Vasoconstrictor responses to des-Arg9-bradykinin under low-tone conditions and vasodilator responses under elevated-tone conditions were antagonized by des-Arg9,[Leu8]-bradykinin, a kinin B1 receptor antagonist, whereas responses under low- and high-tone conditions were not altered by Hoe 140, a kinin B2 receptor antagonist. 4-hydroxy-2-octenal 286-289 kininogen 1 Homo sapiens 38-48 7545124-3 1995 With higher concentrations of GR32191 (10(-7) and 10(-6) M) bradykinin induced a relaxation which was inhibited by indomethacin and by the bradykinin B2 receptor antagonist Hoe 140 (D-Arg0[Hyp3,Thi-5,D-Tic7,Oic8]bradykinin). 4-hydroxy-2-octenal 173-176 kininogen 1 Homo sapiens 60-70 7545124-3 1995 With higher concentrations of GR32191 (10(-7) and 10(-6) M) bradykinin induced a relaxation which was inhibited by indomethacin and by the bradykinin B2 receptor antagonist Hoe 140 (D-Arg0[Hyp3,Thi-5,D-Tic7,Oic8]bradykinin). 4-hydroxy-2-octenal 173-176 kininogen 1 Homo sapiens 139-149 7545124-3 1995 With higher concentrations of GR32191 (10(-7) and 10(-6) M) bradykinin induced a relaxation which was inhibited by indomethacin and by the bradykinin B2 receptor antagonist Hoe 140 (D-Arg0[Hyp3,Thi-5,D-Tic7,Oic8]bradykinin). 4-hydroxy-2-octenal 173-176 kininogen 1 Homo sapiens 139-149 7890486-7 1995 The bradykinin antagonist Hoe 140 (3 x 10(-7) M) prevented the relaxation of ciliary arteries to bradykinin (P < 0.001), but not to acetylcholine. 4-hydroxy-2-octenal 26-29 kininogen 1 Homo sapiens 4-14 7890486-7 1995 The bradykinin antagonist Hoe 140 (3 x 10(-7) M) prevented the relaxation of ciliary arteries to bradykinin (P < 0.001), but not to acetylcholine. 4-hydroxy-2-octenal 26-29 kininogen 1 Homo sapiens 97-107 7955144-3 1994 Vasoconstrictor responses to des-Arg9-bradykinin under low-tone conditions and vasodilator responses under elevated-tone conditions were antagonized by des-Arg9,[Leu8]-bradykinin, a kinin B1 receptor antagonist, whereas responses under low- and high-tone conditions were not altered by Hoe 140, a kinin B2 receptor antagonist. 4-hydroxy-2-octenal 286-289 kininogen 1 Homo sapiens 168-178 1331550-3 1992 The response to bradykinin was antagonized by HOE 140, a bradykinin receptor antagonist, while it was unaffected by MEN 10,376, a tachykinin receptor antagonist, hCGRP(8-37) a calcitonin gene-related peptide (CGRP) receptor antagonist and N-t-BOC-Phe-DLeu-Phe-DLeu-Phe (BPLPLP), an FMLP antagonist. 4-hydroxy-2-octenal 46-49 kininogen 1 Homo sapiens 16-26 8319757-0 1993 Inhibitory effects of Hoe 140 on vasodilator responses to bradykinin in the mesenteric vascular bed of the cat. 4-hydroxy-2-octenal 22-25 kininogen 1 Homo sapiens 58-68 8319757-1 1993 The effect of Hoe 140, a bradykinin B2 receptor antagonist, on vasodilator responses to bradykinin was investigated in the mesenteric vascular bed of the cat under constant flow conditions. 4-hydroxy-2-octenal 14-17 kininogen 1 Homo sapiens 88-98 8319757-2 1993 Injections of bradykinin into the mesenteric vascular bed induced dose-related decreases in perfusion pressure which were reduced significantly following administration of Hoe 140 (D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) (100 micrograms/kg i.v.). 4-hydroxy-2-octenal 172-175 kininogen 1 Homo sapiens 14-24 8319757-2 1993 Injections of bradykinin into the mesenteric vascular bed induced dose-related decreases in perfusion pressure which were reduced significantly following administration of Hoe 140 (D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) (100 micrograms/kg i.v.). 4-hydroxy-2-octenal 172-175 kininogen 1 Homo sapiens 210-220 8383737-7 1993 This higher potency of Hoe 140, and its stability against peptidases, suggests that this compound will be useful in evaluating the role of bradykinin in inflammatory diseases of the airways. 4-hydroxy-2-octenal 23-26 kininogen 1 Homo sapiens 139-149 8319757-5 1993 These results suggest that Hoe 140 is a potent, highly selective, long-acting bradykinin B2 receptor antagonist with little agonistic activity in the mesenteric vascular bed of the cat. 4-hydroxy-2-octenal 27-30 kininogen 1 Homo sapiens 78-88 1331550-3 1992 The response to bradykinin was antagonized by HOE 140, a bradykinin receptor antagonist, while it was unaffected by MEN 10,376, a tachykinin receptor antagonist, hCGRP(8-37) a calcitonin gene-related peptide (CGRP) receptor antagonist and N-t-BOC-Phe-DLeu-Phe-DLeu-Phe (BPLPLP), an FMLP antagonist. 4-hydroxy-2-octenal 46-49 kininogen 1 Homo sapiens 57-67 1282721-4 1992 The effect of BK (10(-8) mol/l) on the [Ca2+]i was inhibited by the BK2 antagonist Hoe 140 (IC50 10(-8) mol/l). 4-hydroxy-2-octenal 83-86 kininogen 1 Homo sapiens 14-16 1282632-6 1992 Mechanical removal of the endothelium or incubation with nitro-L-arginine or the bradykinin2-receptor antagonist Hoe 140 prevented the relaxations to bradykinin and lisinopril. 4-hydroxy-2-octenal 113-116 kininogen 1 Homo sapiens 81-91 21729302-3 2011 Incubation with BK (10.0 microMol/L) for 18 hours increased the migration index 3-fold in comparison to controls or to cells preincubated with the B2R antagonist HOE-140. 4-hydroxy-2-octenal 162-165 kininogen 1 Homo sapiens 16-18